Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex

Objective: We aimed to analyse the effects of age and sex on performance and cost for patients with chronic peripheral neuropathic pain (PNP) who have started treatment with brand name gabapentin versus generic gabapentin (EFG). Methods: We conducted a retrospective multicentre study using electroni...

Full description

Bibliographic Details
Main Authors:	R. Navarro-Artieda, J. Rejas-Gutiérrez, M. Pérez-Paramo, A. Sicras-Mainar
Format:	Article
Language:	English
Published:	Elsevier España 2018-04-01
Series:	Neurología (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2173580818300105

Similar Items

Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
by: A. Sicras-Mainar, et al.
Published: (2018-12-01)

Influencia de la sustitución de medicamentos de marca por genéricos en el cumplimiento terapéutico de la hipertensión arterial y la dislipidemia Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia
by: Antoni Sicras Mainar, et al.
Published: (2010-12-01)

A Cost-Consequences analysis of the effect of Pregabalin in the treatment of peripheral Neuropathic Pain in routine medical practice in Primary Care settings
by: Torrades Sandra, et al.
Published: (2011-01-01)

Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact
by: Antoni Sicras-Mainar, et al.
Published: (2014-12-01)

Los adjusted clinicals groups: Un sistema de clasificación de pacientes por ajuste de riesgos
by: Antonio Sicras-Mainar, et al.
Published: (2013-06-01)

Validación retrospectiva del Johns-Hopkins ACG Case-Mix System en la población Española Validating the Adjusted Clinical Groups [ACG] Case-mix System in a Spanish population setting: a multicenter study
by: Antoni Sicras-Mainar, et al.
Published: (2009-06-01)

Opinión de los médicos de atención primaria sobre el uso de un sistema de ajuste de riesgos: Los adjusted clinical groups
by: Antoni Sicras-Mainar, et al.

Opinión de los médicos de atención primaria sobre el uso de un sistema de ajuste de riesgos: Los adjusted clinical groups
by: Antoni Sicras-Mainar, et al.

Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients ( 2015;39:74-81)
by: Antoni Sicras-Mainar, et al.
Published: (2015-04-01)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
by: Sicras-Mainar A, et al.
Published: (2014-06-01)

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
by: Antoni Sicras-Mainar, et al.
Published: (2015-02-01)

Combinación de metformina frente a inhibidores de la dipeptidilpeptidasa y sulfonilureas en el tratamiento de la diabetes tipo 2: impacto clínico y económico
by: Antoni Sicras-Mainar, et al.

Combinación de metformina frente a inhibidores de la dipeptidilpeptidasa y sulfonilureas en el tratamiento de la diabetes tipo 2: impacto clínico y económico
by: Antoni Sicras-Mainar, et al.

Clinical validity of a population database definition of remission in patients with major depression
by: Salvatella-Pasant Jordi, et al.
Published: (2010-02-01)

Relationship between obesity and antipsychotic drug use in the adult population: A longitudinal, retrospective claim database study in Primary Care settings
by: Antoni Sicras-Mainar, et al.
Published: (2008-03-01)

Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain
by: Javier Rejas-Gutierrez, et al.
Published: (2021-04-01)

Posibilidades de los Grupos Clínicos Ajustados (Ajusted Clinical Groups-ACGs) en el ajuste de riesgos de pago capitativo
by: Antoni Sicras-Mainar, et al.
Published: (2006-01-01)

Costes y patrón de uso de servicios en pacientes que demandan atención por problemas mentales en asistencia primaria Patterns of health services use and costs in patients with mental disorders in primary care
by: Josep Serrat Tarrés, et al.
Published: (2007-08-01)

Uso de recursos y costos asociados a las fracturas en mujeres españolas Use of resources and costs associated to fractures in spanish women
by: Antoni Sicras-Mainar, et al.
Published: (2012-09-01)

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
by: Sicras-Mainar A, et al.
Published: (2019-12-01)

The concept of: Generic drugs and patented drugs Vs brand name drugs and non-proprietary (generic) name drugs.
by: Karan eThakkar, et al.
Published: (2013-09-01)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
by: Fernández-de-Bobadilla Jaime, et al.
Published: (2007-10-01)

Clinical and economic impact of generic versus brand name meropenem use in an intensive care unit in Colombia
by: Karen Ordóñez, et al.
Published: (2019-07-01)

Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study
by: Sicras-Mainar A, et al.
Published: (2020-12-01)

Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study
by: Jesús Molina, et al.
Published: (2023-04-01)

PRICE AND BRAND NAME AS INDICATORS OF QUALITY DIMENSIONS FOR GENERIC DRUGS
by: , Christian Budiman Urbanus, et al.
Published: (2013)

Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
by: Sicras-Mainar A, et al.
Published: (2022-03-01)

Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics
by: Ping Yang, et al.
Published: (2021-09-01)

Elemental impurities analysis in name-brand and generic omeprazole drug samples
by: Fernanda C. Pinheiro, et al.
Published: (2020-02-01)

An open-label prospective clinical study of the efficacy and tolerability of brand-name and generic levetiracetam in the monotherapy of focal epilepsy in adults
by: V. A. Karlov, et al.
Published: (2018-07-01)

Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain
by: Antoni Sicras-Mainar, et al.
Published: (2017-07-01)

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia
by: Antoni Sicras-Mainar, et al.
Published: (2017-09-01)

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia
by: Sicras-Mainar A, et al.
Published: (2014-12-01)

Impact on healthcare resource utilization of multiple sclerosis in Spain
by: Antoni Sicras-Mainar, et al.
Published: (2017-12-01)

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
by: Ameet Sarpatwari, et al.
Published: (2016-02-01)

Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation
by: Ochi N, et al.
Published: (2014-12-01)

Estimación de la comorbilidad crónico sobre el costo sanitario en pacientes ancianos con transtornos neurológicos Estimation of chronic co-morbidity on health costs in elderly patients with neurological disorders
by: Antoni Sicras-Mainar, et al.
Published: (2011-09-01)

Treatment profiles and costs of patients with chronic pain in the population setting
by: Sicras Mainar A, et al.
Published: (2012-01-01)

Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain
by: Jaime Rodríguez Quintosa, et al.
Published: (2022-10-01)

Impacto de la morbilidad, uso de recursos y costes en el mantenimiento de la remisión de la depresión mayor en España: estudio longitudinal de ámbito poblacional Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting
by: Antoni Sicras-Mainar, et al.
Published: (2010-01-01)